Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Cash Flows From Operating Activities
Net loss	$ (25,527)	$ (11,914)
Adjustments to reconcile net income to net cash
Depreciation and amortization	2,034	3,046
Realignment accrual accretion	142	161
Provision for bad debt, net	16	58
Reversal of contingent consideration accrual	0	(1,557)
Non-cash loss on sale of Pharmakon		6,868
Stock-based compensation	1,791	1,936
Asset impairments	23,517	0
Non-cash facilities realignment	69	0
Other changes in assets and liabilities:
(Increase) decrease in accounts receivable	(1,054)	1,397
Decrease in unbilled costs	638	770
Increase in other current assets	(758)	(1,797)
(Increase) decrease in other long-term assets	(7)	2,617
(Decrease) increase in accounts payable	(751)	873
(Decrease) increase in unearned contract revenue	(1,381)	2,465
Decrease in accrued salaries and bonus	(1,609)	(2,381)
(Decrease) increase in accrued liabilities	(5,913)	1,817
Decrease in long-term liabilities	(1,493)	(2,374)
Net cash (used in) provided by operating activities	(10,286)	1,985
Cash Flows From Investing Activities
Purchase of property and equipment	(1,112)	(343)
Net cash used in investing activities	(1,112)	(343)
Cash Flows From Financing Activities
Cash paid for repurchase of restricted shares	(156)	(16)
Net cash used in financing activities	(156)	(16)
Net (decrease) increase in cash and cash equivalents	(11,554)	1,626
Cash and cash equivalents – beginning	64,337	62,711
Cash and cash equivalents – ending	52,783	64,337
Cash paid for taxes	$ 175	$ 37